Ristova

Ristova was the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukaemia. Ristova attacks these cells both directly and together with the body’s immune system.

Ristova is approved for the treatment of adults with previously untreated and relapsed/refractory follicular lymphoma, non-progressing (including stable disease) follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and relapsed/refractory chronic lymphocytic leukaemia. In pediatric patients aged 6 months and older, it is approved for the treatment of previously untreated, advanced stage, CD20-postive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma,  or mature B-cell acute leukemia. It is also approved for the treatment of adults with rheumatoid arthritis and pemphigus vulgaris, and both adults and pediatric patients 2 years and older in granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis (GPA/MPA).

In case of any adverse events or safety queries, please contact:

If you have a scientific query related to one of Roche's products, please contact:

M-PK-00001707